Anti-Human NGcGM3 Recombinant Antibody (Racotumomab) (CAT#: TAB-H58)

Figure 1 Antitumor protection against spontaneous lung nodule formation by immunization with racotumomab-alum.

Mice were inoculated subcutaneously with 3LL cells and immunized with racotumomab-alum at a dose of 50 μg, as described in "Materials and Methods." Subcutaneous primary tumor growth.

Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., & Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in oncology, 2, 160.

Figure 2 Effects of racotumomab-alum immunization and chemotherapy on spontaneous lung nodule formation.

Mice were inoculated subcutaneously with 3LL cells, and then immunized with racotumomab-alum (raco-alum) at 50 μg/dose and/or administered with pemetrexed (100 mg/kg).

Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., & Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in oncology, 2, 160.

Figure 3 NeuGc-specific humoral response elicited by racotumomab-alum vaccination.

Mice were challenged subcutaneously with 3LL cells preincubated or not with purified NeuGc, and immunized with racotumomab-alum (raco-alum) at 50 μg/dose. Flow cytometric analysis.

Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., & Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in oncology, 2, 160.

Figure 4 Racotumomab-alum induces NeuGc-specific humoral response.

Mice were challenged subcutaneously with 3LL cells preincubated or not with purified NeuGc, and immunized with racotumomab-alum (raco-alum) at 50 μg/dose. Percent of recognized X63 cells.

Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., & Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in oncology, 2, 160.

Figure 5 Immune response induced in racotumomab/alum-vaccinated patients.

Survival of patients with cytotoxic antibodies killing 30% or more (red line) L1210 cells versus patients with less than 30% lysis (blue line).

Hernández, A. M., & Vázquez, A. M. (2015). Racotumomab–alum vaccine for the treatment of non-small-cell lung cancer. Expert review of vaccines, 14(1), 9-20.

Figure 6 Maximal titers of anti-racotumomab and anti-NeuGc-GM3 antibody responses for all evaluable patients in each dose level.

Specificity controls are shown as empty circles (mouse IgG1 isotype control) and empty lozenges (NeuAc-GM3 ganglioside).

Cacciavillano, W., Sampor, C., Venier, C., Gabri, M. R., de Dávila, M. T., Galluzzo, M. L., ... & Chantada, G. L. (2015). A Phase I Study of the Anti‐Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies. Pediatric blood & cancer, 62(12), 2120-2124.